» Articles » PMID: 19335878

Mapping SF-36 Onto the EQ-5D Index: How Reliable is the Relationship?

Overview
Publisher Biomed Central
Specialty Public Health
Date 2009 Apr 2
PMID 19335878
Citations 86
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Mapping from health status measures onto generic preference-based measures is becoming a common solution when health state utility values are not directly available for economic evaluation. However the accuracy and reliability of the models employed is largely untested, and there is little evidence of their suitability in patient datasets. This paper examines whether mapping approaches are reliable and accurate in terms of their predictions for a large and varied UK patient dataset.

Methods: SF-36 dimension scores are mapped onto the EQ-5D index using a number of different model specifications. The predicted EQ-5D scores for subsets of the sample are compared across inpatient and outpatient settings and medical conditions. This paper compares the results to those obtained from existing mapping functions.

Results: The model including SF-36 dimensions, squared and interaction terms estimated using random effects GLS has the most accurate predictions of all models estimated here and existing mapping functions as indicated by MAE (0.127) and MSE (0.030). Mean absolute error in predictions by EQ-5D utility range increases with severity for our models (0.085 to 0.34) and for existing mapping functions (0.123 to 0.272).

Conclusion: Our results suggest that models mapping the SF-36 onto the EQ-5D have similar predictions across inpatient and outpatient setting and medical conditions. However, the models overpredict for more severe EQ-5D states; this problem is also present in the existing mapping functions.

Citing Articles

Comparison of preference-based health-related quality of life measures for chronic neck pain: a pooled analysis of data from three RCTs.

Lee S, Kim S, Nam D, Park Y, Kim E, Ha I BMJ Open. 2024; 14(12):e086104.

PMID: 39725423 PMC: 11683893. DOI: 10.1136/bmjopen-2024-086104.


The Correlation Between Body Mass Index and Health-Related Quality of Life: Data from Two Weight Loss Intervention Studies.

Kral P, Holst-Hansen T, Olivieri A, Ivanescu C, Lamotte M, Larsen S Adv Ther. 2024; 41(11):4228-4247.

PMID: 39316288 PMC: 11480186. DOI: 10.1007/s12325-024-02932-8.


Health state utility estimates for value assessments of novel treatments in Huntington's disease: a systematic literature review.

Sawant R, Paret K, Petrillo J, Koenig A, Wolowacz S, Ronquest N Health Qual Life Outcomes. 2024; 22(1):33.

PMID: 38627749 PMC: 11020898. DOI: 10.1186/s12955-024-02242-1.


Rituximab or cyclosporine A for the treatment of membranous nephropathy: economic evaluation of the MENTOR trial.

Kadatz M, Klarenbach S, So H, Fervenza F, Cattran D, Barbour S Nephrol Dial Transplant. 2024; 39(12):2058-2066.

PMID: 38621719 PMC: 11596091. DOI: 10.1093/ndt/gfae084.


Utility Scores for Risk-Reducing Mastectomy and Risk-Reducing Salpingo-Oophorectomy: Mapping to EQ-5D.

Oxley S, Wei X, Sideris M, Blyuss O, Kalra A, Sia J Cancers (Basel). 2024; 16(7).

PMID: 38611036 PMC: 11010846. DOI: 10.3390/cancers16071358.


References
1.
Lawrence W, Fleishman J . Predicting EuroQoL EQ-5D preference scores from the SF-12 Health Survey in a nationally representative sample. Med Decis Making. 2004; 24(2):160-9. DOI: 10.1177/0272989X04264015. View

2.
Gray A, Rivero-Arias O, Clarke P . Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making. 2006; 26(1):18-29. DOI: 10.1177/0272989X05284108. View

3.
Brazier J, Roberts J, Tsuchiya A, Busschbach J . A comparison of the EQ-5D and SF-6D across seven patient groups. Health Econ. 2004; 13(9):873-84. DOI: 10.1002/hec.866. View

4.
Franks P, Lubetkin E, Gold M, Tancredi D, Jia H . Mapping the SF-12 to the EuroQol EQ-5D Index in a national US sample. Med Decis Making. 2004; 24(3):247-54. DOI: 10.1177/0272989X04265477. View

5.
Shaw J, Johnson J, Coons S . US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005; 43(3):203-20. DOI: 10.1097/00005650-200503000-00003. View